Muscular Dystrophy Association Conference 2025 (MDA)
BackSafety and Efficacy of DYNE-101 in Adults with DM1: Phase 1/2 ACHIEVE Trial Data (presentation)
Safety and Efficacy from the Ongoing Phase 1/2 DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping (poster)
Safety and efficacy from the ongoing Phase 1/2 DELIVER trial of DYNE-251 in males with DMD mutations amenable to exon 51 skipping (presentation)
The FORCETM Platform Enables TfR1-Mediated Delivery of Exon Skipping PMO to the CNS and Resolves Anxiety in a Mouse Model of DMD (poster)